Future of hepatitis C therapy: Development of direct-acting antivirals

Current Opinion in HIV and AIDS

Volumn 6, Issue 6, 2011, Pages 508-513

  Dore, Gregory J ^a,b   Matthews, Gail V ^a,b   Rockstroh, Jürgen ^c  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

^b ST VINCENT S HOSPITAL   (Australia)

^c UNIVERSITY OF BONN   (Germany)

Author keywords

boceprevir; direct acting antivirals; hepatitis C; HIV; telaprevir

Indexed keywords

ASUNAPREVIR; ATAZANAVIR PLUS RITONAVIR; BMS 790052; BOCEPREVIR; EFAVIRENZ; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; PEGINTERFERON ALPHA2A PLUS RIBAVIRIN; PEGINTERFERON ALPHA2B PLUS RIBAVIRIN; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; TELAPREVIR; UNCLASSIFIED DRUG;

ANTIVIRAL THERAPY; DISEASE COURSE; DISEASE SEVERITY; DOSE RESPONSE; DRUG EFFICACY; DRUG TOLERABILITY; GENETIC POLYMORPHISM; HEPATITIS C; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MIXED INFECTION; PATIENT CARE; PATIENT SELECTION; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; REVIEW; TREATMENT DURATION; TREATMENT INDICATION; TREATMENT RESPONSE; VIRAL CLEARANCE;

ANTIVIRAL AGENTS; CLINICAL TRIALS, PHASE II AS TOPIC; CLINICAL TRIALS, PHASE III AS TOPIC; DRUG THERAPY, COMBINATION; HEPACIVIRUS; HEPATITIS C, CHRONIC; HIV INFECTIONS; HUMANS; OLIGOPEPTIDES; PROLINE; PROTEASE INHIBITORS; TREATMENT OUTCOME;

EID: 80054879456     PISSN: 1746630X     EISSN: 17466318     Source Type: Journal    
DOI: 10.1097/COH.0b013e32834b87f8     Document Type: Review

References (22)

1. Hofmann WP, Zeuzem S. A new standard of care for the treatment of chronic HCv infection. Nat Rev Gastroenterol Hepatol 2011; 8:257-264.
2. Flisiak R, Horban A, Gallay P, Bobardt M, et al. The cyclophilin inhibitor Debio- 025 shows potent antihepatitis C effect in patients coinfected with hepatitis C and human immunodeficiency virus. Hepatology 2008; 47:817-826. (Pubitemid 351449673)
3. Poordad F, McCone J Jr, Bacon BR, et al. Boceprevir for untreated chronic HCv genotype 1 infection. N Engl J Med 2011; 364:1195-1206.
4. Bacon BR, Gordon SC, Lawitz E, et al. Boceprevir for previously treated chronic HCv genotype 1 infection. N Engl J Med 2011; 364:1207-1217.
5. Jacobson IM, McHutchison JG, Dusheiko G, et al. Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med 2011; 364:2405-2416.
6. Zeuzem S, Andreone P, Pol S, et al. Telaprevir for retreatment of HCv infection. N Engl J Med 2011; 364:2417-2428.
7. Sherman KE, Flamm SL, Afdhal NH, et al. Telaprevir in combination with peginterferon alfa2a and ribavirin for24or48weeks in treatment naïve genotype 1 HCv patients who have achieved an extended rapid viral response: final results of phase vILLUMINATE study. Hepatology 2010; 52:401a-402a.
8. Imhof I, Simmonds P. Genotype differences in susceptibility and resistance development of hepatitis C virus to protease inhibitors telaprevir (vX-950) and danoprevir (ITMN-191). Hepatology 2011; 53:1090-1099.
9. Foster GR, Hezode C, Bronowicki JP et al. Telaprevir alone or with peginterferon and ribavirin reduces HCv RNA in patients with chronic genotype 2 but not vinfections. Gastroenterology. doi: 10.1053/j.gastro.2011.05.046.
10. Freeman AJ, Dore GJ, Law MG, et al. Estimating progression to cirrhosis in chronic hepatitis C virus infection. Hepatology 2001; 34:809-816. (Pubitemid 32928008)
11. Thein HH, Yi Q, Dore GJ, Krahn MD. Natural history of hepatitis C virus infection in HIv-infected individuals and the impact of HIv in the era of highly active antiretroviral therapy: a meta-analysis. AIDS 2008; 22:1979-1991.
12. Suppiah v, Moldovan M, Ahlenstiel G, et al. IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy. Nat Genet 2009; 41:1100-1104.
13. Ge D, Fellay J, Thompson AJ, et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 2009; 461:399-401.
14. Rallon NI, Soriano v, Naggie S, et al. IL28B gene polymorphisms and viral kinetics in HIv/hepatitis C virus-coinfected patients treated with pegylated interferon and ribavirin. AIDS 2011; 25:1025-1033.
15. Chayama K, Hayes CN, Abe H, et al. IL28B but not ITPA polymorphism is predictive of response to pegylated interferon, ribavirin, and telaprevir triple therapy in patients with genotype 1 hepatitis C. J Infect Dis 2011; 204:84-93.
16. Pawlotsky JM. Treatment failure and resistance with direct-acting antiviral drugs against hepatitis C virus. Hepatology 2011; 53:1742-1751.
17. Kwo PY, Lawitz EJ, McCone J, et al. Efficacy of boceprevir, an NSvprotease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatmentnaive patients with genotype 1 hepatitis C infection (SPRINT-1): an openlabel, randomised, multicentre phase 2 trial. Lancet 2010; 376:705-716.
18. Sulkowski M, Dieterich D, Sherman K, et al. Interim analysis of a phase 2a double-blind study of TvR in combination with pegIFN-a2a and RBv in HIv/ HCv co-infected patients. In: 18th Conference on Retroviruses and Opportunistic Infections. San Francisco; 2011. p. 164LB.
19. Lok A, Gardiner D, Lawitz E, et al. Quadruple therapy with BMS-790052, BMS-650032 and PEG-IFN/RBv for 24 weeks results in 100% SvR12 in HCv genotype 1 null responders. J Hepatol 2011; 54:S536.
20. Rong L, Dahari H, Ribeiro RM, Perelson AS. Rapid emergence of protease inhibitor resistance in hepatitis C virus. Sci Transl Med 2010; 2:30ra32. 21
21. Gane EJ, Roberts SK, Stedman CA, et al. Oral combination therapy with a nucleoside polymerase inhibitor (RG7128) and danoprevir for chronic hepatitis C genotype 1 infection (INFORM-1): a randomised, double-blind, placebo-controlled, dose-escalation trial. Lancet 2010; 376:1467-1475.
22. Lalezari J, Lawitz E, Rodriguez-Torres M, et al. Once daily PSI-7977 plus PEGIFN/RBv in a phase 2b trial: rapid virologic suppression in treatmentnaive patients with GT2/GT3. J Hepatol 2011; 54:S28.